ミボレロン
ミボレロンは強力な**アンドロゲン、アナボリック、および抗ゴナドトロピン**作用を持つ19-ノルステロイドです。 * 以前はCheque® Dropsとして販売されていましたが、現在は入手が困難であり、主に調剤薬局を通じて入手可能です。米国では**スケジュールIII規制物質**に指定されています。 * **臨床用途**には、雌犬の発情抑制、偽妊娠、および重度の乳汁漏出症の治療が含まれます。 > **警告:** ミボレロンは猫に対する治療域が非常に狭く、毒性が高いため、猫には**絶対に使用しないでください**。
作用機序: Mibolerone exerts its effects via a **negative feedback mechanism** on the anterior pituitary gland. * **Blocks luteinizing hormone (LH)** release → prevents follicular maturation → inhibits ovulation and corpus luteum development. * The net result is the suppression of the estrous cycle if administered prior to (up to 30 days) the onset of proestrus. * After discontinuation, the next estrus typically occurs within 7-200 days (average 70 days).
動物種別の用量
- Suppression of estrus · 0.5-11 kg: 30 micrograms (0.3 mL) PO per day; 12-22 kg: 60 micrograms (0.6 mL) PO per day; 23-45 kg: 120 micrograms (1.2 mL) PO per day; >45 kg: 180 micrograms (1.8 mL) PO per day. German shepherds or German shepherd crosses: 180 micrograms (1.8 mL) PO per day; regardless of weight · PO · q24h · Treatment must begin at least 30 days prior to proestrus · If dog comes into estrus after receiving the drug for 30 or more days, stop drug and determine that the dog is not pregnant before resuming therapy. If owner compliance has been determined, increase dosage by 20-50%.
- Pseudocyesis (false pregnancy) · 10 times the dosage listed above for suppression of estrus · PO · q24h · 5 days
- Pseudocyesis (false pregnancy) · 16 micrograms/kg · PO · q24h · 5 days
- Cystic endometrial hyperplasia (CEH) · 30 micrograms/25lb. body weight · PO · q24h · 6 months
- Treatment of severe galactorrhea · 8-18 micrograms/kg · PO · q24h · 5 days · Once discontinued, prolactin may surge and galactorrhea resume.
用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。
投与経路
禁忌
- Perianal adenoma or perianal adenocarcinoma
- Other androgen-dependent neoplasias
- Pregnant or lactating bitches
- Patients with ongoing or a history of liver or kidney disease
- Bedlington Terriers
- Cats
有害事象
- Premature epiphyseal closure (in prepuberal females)
- Clitoral enlargement / hypertrophy
- Vaginitis / Vulvovaginitis
- Increased body odor
- Abnormal behavior (e.g., riding/mounting behavior)
- Urinary incontinence
- Voice deepening
- Enhanced clinical signs of seborrhea oleosa
- Epiphora (tearing)
- Hepatic changes (intranuclear hyaline bodies) and rare hepatic dysfunction
- Increased kidney weight
- Fatalities, thyroid dysfunction, and pancreatic dysfunction (in cats)
薬物相互作用
- Phenytoin · Increased seizure activity has been reported in a dog previously controlled on phenytoin.
- Progestins · Should generally not be used concurrently.
- Estrogens · Should generally not be used concurrently.
モニタリング
- Clinical signs of estrus
- Liver function tests (baseline, annual, or as needed)
- Physical examination of genitalia
過量投与
In dogs, the drug did not cause death in doses up to 30,000 micrograms/kg/day when administered to beagles for 28 days. In cats, dosages as low as 120 micrograms/day have resulted in fatalities.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。